Oral gingival delivery systems from chitosan blends with hydrophilic polymers

被引:85
作者
Khoo, CGL
Frantzich, S
Rosinski, A
Sjöström, M
Hoogstraate, J
机构
[1] Pharmaceut & Analyt R&D, Molndal, Sweden
[2] AstraZeneca, Discovery Drug Metab & Pharmacokinet & Bioanalyt, Molndal, Sweden
[3] AstraZeneca, Discovery Drug Metab & Pharmacokinet, Sodertalje, Sweden
关键词
oral gingival delivery; chitosan; blends; hydrophilic polymers; blend miscibility; bioavailability;
D O I
10.1016/S0939-6411(02)00155-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chitosan blends with hydrophilic polymers including polyvinylalcohol (PVA), polyethyleneoxide (PEO) and polyvinylpyrrolidone (PVP), were investigated as candidates for oral gingival delivery systems. The bioavailabilty conferred by the chitosan blend delivery systems, as concluded from dog studies, was shown to be comparable to that based on chitosan alone, especially for those blends involving high molecular weight hydrophilic polymers. Results from differential scanning calorimetry and dynamic mechanical thermal analysis, Fourier transform infrared spectroscopy and tensile testing, indicated that the chitosan/PEO and chitosan/PVP blends showed evidence of miscibility in all blend ratios studied, while the chitosan/PVA blend only showed evidence of interaction for the (50:50) and (80:20) blends, but not for the (20:80) blend. However, even a phase separated system may show interesting and exploitable properties, as evidenced by the tensile testing data for the high molecular weight PVA blend (20:80). The study also indicated that chitosan blends were superior in other properties compared to chitosan alone. These included improved comfort and reduced irritation, ease of processing, improved film quality, improved flexibility, and enhanced dissolution. Blends of chitosan with different hydrophilic polymers could thus be promising candidates for formulation in oral mucosal delivery systems. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 25 条
[1]  
Akbuga J., 1995, J PHARM ADV, V1, P3
[2]   Preparation and properties of modified chitosan films for drug release [J].
Angelova, N ;
Manolova, N ;
Rashkov, I ;
Maximova, V ;
Bogdanova, S ;
Domard, A .
JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, 1995, 10 (04) :285-298
[3]  
BACKSTROM M, 1997, ASTRAZENECA INTERNAL
[4]   Blend of chitosan acetate salt with poly(N-vinyl-2-pyrrolidone):: Interaction between chain-chain [J].
Cao, SG ;
Shi, YQ ;
Chen, GW .
POLYMER BULLETIN, 1998, 41 (05) :553-559
[5]  
COLEMAN MM, 1978, J MACROMOL SCI R M C, VC16, P197
[6]   Effect of chitosan on epithelial permeability and structure [J].
Dodane, V ;
Khan, MA ;
Merwin, JR .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (01) :21-32
[7]   Chitosan: A unique polysaccharide for drug delivery [J].
Felt, O ;
Buri, P ;
Gurny, R .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1998, 24 (11) :979-993
[8]   Drug delivery via the buccal mucosa [J].
Hoogstraate, JAJ ;
Wertz, PW .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1998, 1 (07) :309-316
[9]   Chitosan: properties, preparations and application to microparticulate systems [J].
Kas, HS .
JOURNAL OF MICROENCAPSULATION, 1997, 14 (06) :689-711
[10]   RATIO METHOD FOR ANALYZING IR-SPECTRA OF MIXTURES [J].
KOENIG, JL ;
DESPOSITO, L ;
ANTOON, MK .
APPLIED SPECTROSCOPY, 1977, 31 (04) :292-295